Print Page   |   Sign In   |   Join!
News & Press: Legislative and Regulatory News

3-26-2020 COVID-19 Update

Thursday, March 26, 2020   (0 Comments)
Posted by: Gabrielle Webster
Share |
  

        

  


Continuing Saga of COVID-19

Dear Colleagues – Below is your daily e-mail news from PSHP. We welcome all feedback and contributions.  

PSHP and other Pennsylvania organizations continue to work towards getting the Governor to add a waiver authorizing pharmacists NOT to fill prescriptions for Hydroxychloroquine, Chloroquine, as well as, Azithromycin, Kaletra, and other related medications, other than for a COVID-19 diagnosis when the diagnosis has been confirmed by a positive test result and for those already taking these medications for other chronic FDA-approved indications.


Here is another example from one of our local hospital members on how they are dealing with the COVID-19 crisis concerning cloth material for masks, as a last resort to prevent droplet transmission and continue sterile compounds.  Note: it is very important for staff to properly launder these cloth masks each day.  Wash in hot water with bleach to reduce microbial burden.  Use the dryer where the fabric allows.
                                         
Question: What type of material is best for cloth-made masks?

Answer: Due to the current mask shortage facing the world amidst COVID-19, there has been a push to find alternative materials to make masks. N-95 respirators and surgical masks are still the first-choice for PPE to protect healthcare professionals. However, as supplies dwindle, desperate measures are being taken to make masks using cloth or other readily available material.
                    
Also provided below are some supporting studies (click the title to access the PDF) to use in determining the best possible alternatives to regular PPE within your institution, should you need to make that decision.

Supporting Studies:


Webinar: Joint Commission Accreditation and Certification Chart-Abstracted Measure Manual Updates effective July 1, 2020

March 26, 2020  60 min (12:00 pm – 1:00 pm ET)

More Information


ACETAMINOPHEN (TYLENOL®) OR IBUROFEN (MOTRIN®) – Which is better for Coronaviris?  

On March 14, the French minister of health, Olivier Véran, issued a statement recommending that people infected with the novel coronavirus, which causes a potentially deadly upper respiratory disease called COVID-19, not use ibuprofen or aspirin to treat symptoms of the disease. Instead, he urged followers to take acetaminophen, noting that the use of non-steroidal anti-inflammatories such as ibuprofen could actually worsen the illness caused by the new coronavirus.

These drugs are “helpful” for symptomatic treatment only and are not a cure. By decreasing inflammation, they can decrease pain, swelling, redness, and other symptoms that may be associated with inflammation. However, the side effects of NSAIDs can include stomach pain and heartburn, stomach ulcers, nausea, vomiting, diarrhea or constipation, allergic reactions, liver or kidney problems, and high blood pressure. [View source material here.]

More Evidence Needed:  The need for more evidence concerning using ibuprofen in conjunction with coronavirus infection is a common refrain among experts. Dr. Jeffrey Klausner, Professor of Medicine and Public Health at the University of California Los Angeles Fielding School of Public Health, says that currently, “we know very little” about how using ibuprofen may impact a patient’s experience with COVID-19.

*Lesson for Now:  Preferred Use is Acetaminophen, but if all that is available is Ibuprofen – USE IT.

 

Thank you for your active participation in the profession of pharmacy!   

Larry Jones

PSHP Executive Director


Other suggestions or related issues?

To make this information meaningful, please provide us feedback on what you would like to see in this BLAST and all are invited to please contribute information to post by submitting your information to us via email.  

Disclaimer:  The information provided in these e-mail blasts is intended to be shared across all Directors of Pharmacy in Pennsylvania and our PSHP members for individual determination, to assist facilities with product and/or service alternatives (suggestions only) as appropriate for Peer Review.  It is not intended to be interpreted as a mandate or as a PSHP-supported modification nor as an acceptable regulation alternative.  For this the PA State Board of Pharmacy has the final authority.


Pennsylvania Society of Health-System Pharmacists
PO Box 22520, Philadelphia, PA 19110
info@pshp.org | (978) 364-5097 | www.pshp.org


Membership Management Software Powered by YourMembership  ::  Legal